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Background: An in-clinic assay for equine serum amyloid A (SAA) analysis, Equinostic EVA1, was evaluated for use
in a clinical setting. Stability of SAA in serum samples was determined.
Methods: Intra- and inter- assay variation of the in-clinic method was determined. The in-clinic method (EVA1)
results were compared to a reference method (Eiken LZ SAA) with 62 patient samples. For samples with SAA
concentrations within the assay range of EVA1 (10-270 mg/L), differences between the methods were evaluated in
a difference plot. Linearity under dilution was evaluated in two samples. Stability of SAA in three serum pools
stored at 4°C and approximately 22°C was evaluated with the reference method day 0, 1, 2, 4, 7, 17 and analysed
with a two-way ANOVA.
Results: The imprecision (coefficient of variation, CV) for the in-clinic method was acceptable at higher SAA
concentrations with CV values of 7,3-12%, but poor at low SAA concentrations with CV values of 27% and 37% for
intra- and inter-assay variation respectively. Recovery after dilution was 50-138%. The in-clinic assay and the
reference method identified equally well horses with low (<10 mg/L) and high (>270 mg/L) SAA concentrations.
Within the assay range of the in-clinic method, 10-270 mg/L, the difference between the two methods was slightly
higher than could be explained by the inherent imprecision of the assays. There were no significant changes of
serum SAA concentrations during storage.
Conclusions: The in-clinic assay identified horses with SAA concentrations of <10 mg/L and >270 mg/L in a
similar way as the reference method, and provided an estimate of the SAA concentration in the range of 10-270
mg/L. The imprecision of the in-clinic method was acceptable at high SAA concentrations but not at low
concentrations. Dilution of samples gave inconsistent results. SAA was stable both at room temperature and
refrigerated, and thus samples may be stored before analysis with the reference method.
Background
Increased concentration of serum amyloid A (SAA), a
major acute phase protein, is the most sensitive method
to identify inflammation in horses. Healthy horses have
very low SAA concentrations, whereas there is a rapid
and large increase of SAA following inflammatory sti-
mulus [1-3]. Other tests of inflammation such as total
leukocyte counts, differential leukocyte counts and fibri-
nogen concentration have been more readily available to
equine practitioners, but are rather insensitive indicators
of inflammatory diseases in horses [4-6]. SAA rises fast
after an inflammatory stimulus and, due to its short
half-life in serum [7], the concentration diminishes
rapidly during recovery. SAA is a non-specific inflam-
matory marker and increased concentrations are seen in
bacterial infections [3,8-10], viral infections [1,11] and in
sterile inflammation [6]. The increase in SAA concentra-
tion has been shown to correlate with severity of clinical
signs [11] and with the intensity of surgical trauma [12].
However, there is also individual variation as a similar
experimentally induced trauma elicited varying
responses of SAA among individuals [3].
Methods for determining equine SAA have been cum-
bersome to perform or require automated analysers.
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radial immunodiffusion [2], slide reversed passive latex
agglutination [13], non-competitive chemiluminescence
enzyme immunoassay [3], ELISA [14] and assays using
the latex agglutination immunoturbidometric principle
[15,16]. An in-clinic test intended for measuring equine
SAA, Equinostic EVA1 (Equinostic ApS, Birkerød, Den-
mark), has become available and was reported to have
good performance in a laboratory setting [17]. In this
study the method was evaluated in a clinical setting at a
private veterinary hospital. Additionally the stability of
SAA in serum, analysed with an immunoturbidometric
method used at a referral laboratory, was investigated.
Methods
SAA analyses
The in-clinic method EVA1 is an immunoturbidometric
assay where a reaction between SAA and anti-SAA-anti-
bodies causes an increased turbidity, which is measured
with a spectrophotometer. Analysis with the in-clinic
method EVA1 (lot 78005) was performed according to
the manufacturer’si n s t r u c t i o n sa sp r e v i o u s l yd e s c r i b e d
[17], at a regional equine hospital (Strömsholm Referral
Animal Hospital, Strömsholm, Sweden). The sample
volume of 2 μl serum was measured with a capillary
tube. Written information about five standard points
and their respective absorbance was enclosed with each
lot of reagent, and a calibration curve was created by
transferring these data to the EVA1 instrument. The
manufacturer reported an assay range of approximately
10-300 mg/L, but 270 mg/L was set as the upper limit
in this study, because this was equal to the concentra-
tion of the highest standard point in the actual lot. An
equine serum pool was used as control and was ana-
lysed once every week.
The reference method Eiken (LZ test SAA, Eiken Che-
mical Co Tokyo, Japan) is a human immunoturbido-
metric assay previously validated in horses [15]. Analyses
with the reference method were performed at the Clinical
Pathology Laboratory at the University Animal Hospital
(Swedish University of Agricultural Sciences, Uppsala,
Sweden) according to the manufacturer’s instructions
with an automated analyser, Konelab (Konelab PRIME
3 0 ,T h e r m oF i s h e rS c i e n t i f i cI n c ,W a l t h a m ,U S A ) .S a m -
ples with SAA concentrations of >250 mg/L were diluted
1:6 with distilled water on the automated analyser. An
equine serum pool and a human commercial control
sample (Trulab P, Diagnostic Systems International,
Holzheim, Germany) were used as controls and were
analysed daily. Inter-assay variation of the reference
method was approximately 7.5% (data not shown).
Animals and samples
Intra- and inter-assay variations were determined with
two serum pools prepared by mixing sera from 5 equine
patients. Four of the 5 horses had elevated SAA concen-
trations and 1 had SAA concentration of < 5 mg/L. In a
comparison study blood samples from 62 adult equine
patients at Strömsholm Referral Animal Hospital were
collected from the jugular vein into serum clot tubes.
The selection criterion was that the clinician had also
requested plasma fibrinogen. Samples were centrifuged
at 1000 g for 10 minutes after clotting was completed.
For the stability study three serum pools (pool A-C)
were prepared from sera from 6 different horses, 5 of
which had elevated SAA concentrations and 1 that had
SAA concentration of < 5 mg/L.
Characteristics of in-clinic assay (EVA1)
Intra-assay variation was determined by analyzing two
serum pools with SAA concentrations of 12 mg/L and
197 mg/L respectively, ten consecutive times. The coef-
ficients of variation (CV) in % were calculated (standard
deviation divided by mean value × 100) to describe
imprecision. Inter-assay variation was determined by
analyzing, on 10 different days within a period of 30
days, the two serum pools mentioned above which were
frozen in aliquots at -20°C until analysis. Only the vial
needed for each analytical run was thawed. Intra-assay
variation was also measured by analysing a commercial
control sample from Equinostic, with a stated mean
value of 150 mg/L, ten times in a row.
Inaccuracy was evaluated by diluting two samples with
SAA concentrations of 212 mg/L and 255 mg/L 1:2, 1:4
and 1:8 with PBS, a buffer solution (0.15 M, pH 7.4)
provided by the manufacturer.
Comparison between in-clinic method (EVA1) and
reference method (Eiken)
All samples in the comparison study were analysed with
the in-clinic assay at Strömsholm within 5 hours of col-
lection. These samples were handled as clinical samples,
which meant they were analyzed among other patient
samples in order that they arrived to the laboratory
unless labelled as acute. One laboratory technician per-
formed all the analyses on the in-clinic assay. Samples
were then transported to the University laboratory for
analysis with the reference method, Eiken. Forty-nine of
the samples were analysed within 24 hours, 6 samples
within 2 days and 7 samples within 3-5 days. Samples
were continuously stored at 4°C.
Storage stability of SAA in serum
Stability of SAA in serum was investigated with three
serum pools (pool A, B and C) with SAA concentrations
of 1060, 197 and 73 mg/L, respectively. The serum
pools were stored at both 4°C and at room temperature
(approximately 22°C). They were analysed with the
reference method on day 0, 1, 2, 4, 7 and 17.
Statistical analyses
Arithmetic means, standard deviations and intra- and
inter-assay CV were calculated using descriptive
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USA). The differences between the in-clinic and the
reference method in the comparison study were com-
pared with the limits of inherent imprecision in a differ-
ence plot [18] (Analyze-it Software Ltd, Leeds, UK). The
combined imprecision was calculated by using the inter-
assay variations of EVA1 and Eiken (CV 12% and 7.5%





rage stability was evaluated by a 2-way ANOVA with
temperature (4°C and 22°C) and time (day 1, 2, 4, 7 and
17) as factors. A significance value of < 0.05 was used.
Results
Characteristics of in-clinic assay (EVA1)
Results from the precision study are shown in table 1
and results from the dilution study in table 2.
Comparison between in-clinic method (EVA1) and
reference method (Eiken)
The assay range of EVA1 was 10-270 mg/L. In the com-
parison study low SAA concentrations of < 10 mg/L
were found in 19 samples (31%) with both the in-clinic
and the reference method. One sample had a SAA con-
centration of <10 mg/L with the in-clinic method and
19 mg/L with the reference method. Thirty one samples
(50%) had SAA concentrations of more than 270 mg/L
with both assays. The maximum assay range of EVA1
was 270 mg/L and therefore dilution of samples would
have been necessary to obtain results greater than 270
mg/L, but were not performed in the present study.
Only 11 samples (18%) had SAA concentrations of 10-
270 mg/L with the in-clinic method (Figure 1 and 2).
The combined imprecision was 14%, calculated by using
the inter-assay variations of both methods. In figure 2
the dashed lines represent the 95% confidence interval
of this combined inherent imprecision [18]. Because 5
of the 11 samples were outside the interval outlined by
the lines, the difference between the two methods was
larger than could be explained by imprecision only.
Storage stability of SAA in serum
There were no statistical significant changes in SAA
concentrations over time in 3 serum pools stored at 4°C
and 22°C (Figure 3), and the variance between days was
not higher than could be explained by the imprecision
of the method. In pool B there was a significant differ-
ence in SAA concentrations between the pool stored at
4°C and 22°C (p = 0.003).
Discussion
The Equinostic EVA1 in-clinic instrument was as effec-
tive as the reference method in identification of horses
with SAA concentrations of < 10 mg/L or > 270 mg/L.
Fifty one of 62 horses in this study belonged to one of
these groups. Only 11 horses had SAA concentrations
of 10-270 mg/L, which reflects the biological behaviour
of SAA since the elevation of SAA in inflammation is
often more than 100-fold [15]. The difference between
the two methods in the range of 10-270 mg/L was
slightly larger than could be explained by the inherent
imprecision of the assays, but the clinical interpretation
would be mild-moderate elevations with both the in-
clinic and the reference method. In the previous valida-
tion study the in-clinic method constantly underesti-
mated the SAA concentration compared to the
reference method [17], but this bias was not seen in the
present study including only 11 samples within this
range.
The imprecision of EVA1 was higher than has been
reported earlier [17]. A possible explanation for this,
and for the differences in the method comparison study,
may be that in this study the analyses were handled as
routine samples in the daily work at the laboratory, and
not as a research project. The person analysing the sam-
ples worked routinely in an acute type laboratory with a
high volume of samples, with many samples expected to
be analysed within 30 minutes. The person performing
the tests was a trained medical technician, working in a
h i g h e rq u a l i t yl a b o r a t o r yw i t ho n l yp r o f e s s i o n a la n d
experienced personnel. Even worse performance might
be expected in a clinic without licensed laboratory pro-
fessionals where laboratory testing is done by the person
available at the time. Some manipulations in the EVA1
method require good laboratory technique and provide
risk of error with inexperienced operators. For example,
the sample volume of 2 μl is so small that variation in
this volume among untrained operators is likely.
At high SAA concentrations the CV of the in-clinic
method for inter-assay variation was 12%, which is
acceptable for clinical purposes considering the biologi-
cal behaviour of SAA. At low SAA concentrations the
precision was poor with a mean CV of 32%. It is recom-
mended that each laboratory using the in-clinic method
evaluate their own imprecision at different
Table 1 Intra- and inter-assay variation in determining
SAA with EVA1







a 12 3.3 27
EVA1 10
b 197 14 7.3
10
c 159 16 9.9
Inter-assay 10
a 22 8.3 37
EVA1 10
b 171 20 12
aSerum pool with low SAA concentration.
bSerum pool with high SAA concentration.
cControl sample from Equinostic with a stated mean value of 150 mg/L.
SD; standard deviation
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cut off values. The manufacturer suggested a reference
value of < 25 mg/L. The EVA1 instrument reported
SAA concentrations out to two decimal places, however,
given the imprecision of the method, should rather be
whole numbers.
The in-clinic method was previously reported to have
an acceptable linearity under dilution [17]. In our study,
the recovery varied considerably (50-138%). It is not
clear whether this was due to manual errors or if there
was a problem with the assay. Results were poorest at
low SAA concentrations, and in this range the high
imprecision could contribute to the inaccurate results.
Dilution of samples would be required to be able to
determine SAA concentrations of > 270 mg/L, and
further investigations of effects of dilutions and accuracy
with the in-clinic assay in a clinical setting would be
required to validate the method for this purpose. The
procedure of diluting a test doubles the reagent costs
and more than doubles the time required for the SAA
analysis.
In this study SAA was stable in both room tempera-
ture and at 4°C. A previous study of stability of SAA in
equine samples stored at room temperature reported
decreased levels of SAA after storage in 3 samples,
whereas SAA concentrations in 10 other samples chan-
ged very little [19]. The reasons why the stability varied
between samples are unknown. In another study where
an equine SAA standard pool was stored at 4°C over a
period of up to two months, no significant changes in
Table 2 Dilution of two SAA samples
SAA (mg/L) SAA calc
(mg/L)
Recovery (%) SAA (mg/L) SAA calc
(mg/L)
Recovery (%)
Undiluted 212 NA NA 255 NA NA
Diluted 1:2 103 106 97 176 128 138
Diluted 1:4 41 53 78 73 64 115
Diluted 1:8 <10 27 - 16 32 50
NA = not applicable
SAA calc = SAA calculated
Figure 1 Method comparison between in-clinic assay (EVA1) and reference assay (Eiken). Eleven samples with SAA concentrations of 10-
270 mg/L (assay range of EVA1) are plotted. The line represents y = x. One sample had a SAA concentration of <10 mg/L with the in-clinic
method and 19 mg/L with the reference method (not shown in this figure). Nineteen samples had SAA concentrations of <10 mg/L with both
methods and 31 samples had SAA concentrations of >270 mg/L with both methods.
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assay variation of the reference method (Eiken) was
approximately 7.5% at the current laboratory, and in the
stability study the variance was not higher than could be
explained by this imprecision. Changes in SAA concen-
trations over time would possibly be discovered if using
a more precise method, but would not likely be of
clinical importance. In pool B there was a significant dif-
ference between SAA concentrations when stored at 4°C
and 22°C respectively, but no similar trend was seen in
the two other serum pools.
In the comparison study samples were analysed on the
in-clinic assay on the day of collection and then stored
up to 5 days at 4°C before analyse on the reference
Figure 2 Difference plot of SAA concentrations measured by in-clinic method (EVA1) and reference method (Eiken). The dashed lines
represent the 95% confidence interval of the combined inherent imprecision of the two assays.
Figure 3 Storage stability of SAA in three serum pools stored at 4°C and approximately 22°C.
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be handled identically, but considering that the storage
stability of SAA was satisfactory using the reference
method, the storage times used in this study should not
affect the results. However, as different antibodies were
used in the two assays it cannot be concluded that the
same stability would be present when analysing SAA
with the in-clinic method. It is possible that some anti-
bodies detect degraded SAA protein, while others do
not. The stability of SAA with the in-clinic method was
not evaluated. As the purpose of the in-clinic method is
to measure SAA without delay, stability of SAA is less
crucial for this assay than for the reference assay, where
samples often need to be transported to a referral
laboratory.
Conclusions
The in-clinic method was effective in identifying horses
with low (< 10 mg/L) or elevated (>270 mg/L) SAA
concentrations and it provided an estimate of the SAA
concentration in the range of 10-270 mg/L. The impre-
cision of the in-clinic method was acceptable at high
SAA concentrations but not at low concentrations. Dilu-
tion of samples gave inconsistent results. SAA was
stable for at least 17 days at room temperature and
refrigerated, and thus samples may be stored before ana-
lysis with the reference method.
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